Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related TEVA
Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Teva launches generic Epzicom in U.S. (Seeking Alpha)
Related RVBD
Riverbed Technology To Deliver Earnings Growth, Experts & Crowd Say
JP Morgan Positive On Brocade Communications' Intent To Acquire SteelApp Assets

Analysts at Canaccord downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “buy” to “hold.” The target price for Teva has been raised from $50 to $45. Teva's shares closed at $37.96 yesterday.

Analysts at FBR Capital downgraded Riverbed Technology (NASDAQ: RVBD) from “outperform” to “market perform.” The target price for Riverbed has been lowered from $28 to $20. Riverbed's shares closed at $20.10 yesterday.

Analysts at Roth Capital downgraded Skullcandy (NASDAQ: SKUL) from “buy” to “neutral.” The target price for Skullcandy is set to $7. Skullcandy's shares closed at $6.61 yesterday.

CRT Capital downgraded Alpha Natural Resources (NYSE: ANR) from “buy” to “fair value.” The target price for Alpha Natural is set to $8. Alpha Natural's shares closed at $8.51 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Sep 2016OppenheimerUpgradesPerformOutperform
Aug 2016Leerink SwannMaintainsOutperform
Aug 2016BTIG ResearchMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (RVBD + ANR)

View Comments and Join the Discussion!